Conv. Plasma
Nigella Sativa
Peg.. Lambda

All favipiravir studies
Meta analysis
Home COVID-19 treatment researchFavipiravirFavipiravir (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 38% Improvement Relative Risk Favipiravir for COVID-19  Cilli et al.  LATE TREATMENT Is late treatment with favipiravir beneficial for COVID-19? Retrospective 46 patients in Turkey Lower mortality with favipiravir (not stat. sig., p=0.51) Cilli et al., Respiratory Medicine and.., Mar 2022 Favors favipiravir Favors control

Characteristics and outcomes of COVID-19 patients with IPF: A multi-center retrospective study

Cilli et al., Respiratory Medicine and Research, doi:10.1016/j.resmer.2022.100900
Mar 2022  
  Source   PDF   All Studies   Meta AnalysisMeta
Retrospective 46 idiopathic pulmonary fibrosis patients with COVID-19 in Turkey, showing lower mortality with favipiravir in unadjusted results, without statistical significance. This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
risk of death, 37.5% lower, RR 0.62, p = 0.51, treatment 5 of 23 (21.7%), control 8 of 23 (34.8%), NNT 7.7, day 30.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Cilli et al., 3 Mar 2022, retrospective, Turkey, peer-reviewed, 10 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperFavipiravirAll
Characteristics and outcomes of COVID-19 patients with IPF: A multi-center retrospective study
Aykut Cilli, Ismail Hanta, Fatih Uzer, Funda Coskun, Can Sevinc, Pelin Pınar Deniz, Mehmet Parlak, Ersoy Altunok, Kemal Can Tertemiz, Ahmet Ursavas
Respiratory Medicine and Research, doi:10.1016/j.resmer.2022.100900
Background: There are few data on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (COVID-19) infection in patients with idiopathic pulmonary fibrosis (IPF). The objective of this study is to describe the characteristics and outcomes of IPF patients confirmed COVID-19 infection. Methods: In this retrospective, multi-center, cohort study, patients from 4 hospital medical records with known IPF and a COVID-19 diagnosis were identified. Demographic and clinical outcome data were abstracted through a review of electronic medical records. Results: Records for 46 patients with IPF and COVID-19 were abstracted. The mean age was 65 § 10 years. The most common symptom was dyspnea, followed by fever and cough. Ground-glass opacities (n = 35, 83.3%) and consolidations (n = 11, 26.1%) were the main imaging features of the disease in thorax computed tomography (CT). Twenty-four patients (52.1%) required hospitalization. Among the hospitalized patients, 16 (66.6%) were admitted to the intensive care unit (ICU), and 10 (41.6%) underwent invasive mechanical ventilation. Thirteen patients (28.2%) died of COVID-19 complications. Mortality rate was significantly associated with lower DLCO/VA, long term oxygen therapy and consolidation finding on CT of thorax (p<0.05). On multivariable analysis, neither factor was associated with hospitalization or mortality. Conclusions: IPF patients represent a vulnerable population for COVID-19, according to the high rate of hospitalization, ICU requirement, and mortality rate. Measures to minimize the risk of COVID-19 infection remain key to protect IPF patients.
Conflict of Interest None.
Aloufi, Traboulsi, Ding, Fonseca, Nair et al., Angiotensin-converting enzyme 2 expression in COPD and IPF fibroblasts: the forgotten cell in COVID-19, Am J Physiol Lung Cell Mol Physiol, doi:10.1152/ajplung.00455.2020
Drake, Docherty, Harrison, Quint, Adamali et al., Outcome of hospitalization for COVID-19 in patients with interstitial lung disease. An international multicenter study, Am J Respir Crit Care Med, doi:10.1164/rccm.202007-2794OC
Esposito, Menon, Ghosh, Putman, Fredenburgh et al., Increased odds of death for patients with interstitial lung disease and COVID-19: a case-control study, Am J Respir Crit Care Med, doi:10.1164/rccm.202006-2441LE
Gallay, Uzunhan, Borie, Lazor, Rigaud et al., Risk factors for mortality after COVID-19 in patients with preexisting interstitial lung disease, Am J Respir Crit Care Med, doi:10.1164/rccm.202007-2638LE
George, Wells, Jenkins, Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy, Lancet Respirat Med, doi:10.1016/S2213-2600(20)30225-3
Huang, Zhang, Chen, Zhang, Wei et al., Clinical characteristics of COVID-19 in patients with pre-existing ILD: a retrospective study in a single center in Wuhan, China, J Med Virol, doi:10.1002/jmv.26174
Lee, Choi, Yang, Lee, Park et al., Interstitial lung disease increases susceptibility to and severity of COVID-19, Eur Respir J, doi:10.1183/13993003.04125-2020
Li, Liu, Hsu, Lin, Hsu et al., Upregulation of ACE2 and TMPRSS2 by particulate matter and idiopathic pulmonary fibrosis: a potential role in severe COVID-19, Part Fibre Toxicol, doi:10.1186/s12989-021-00404-3
Li, Wu, Wu, Guo, Chen et al., The clinical and chest CT features associated with severe and critical COVID-19 pneumonia, Invest Radiol, doi:10.1097/RLI.0000000000000672
Naqvi, Lakhani, Sohail, Maurer, Sofka et al., Patients with idiopathic pulmonary fibrosis have poor clinical outcomes with COVID-19 disease: a propensity matched multicentre research network analysis, BMJ Open Respir Res, doi:10.1136/bmjresp-2021-000969
Pascarella, Strumia, Piliego, Bruno, Buono et al., COVID-19 diagnosis and management: a comprehensive review, J Intern Med, doi:10.1111/joim.13091
Podolanczuk, Richeldi, COVID-19 and interstitial lung disease: keep them separate, Am J Respir Crit Care Med, doi:10.1164/rccm.202010-3918ED
Raghu, Collard, Egan, Martinez, Behr et al., An Official ATS/ ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management, Am J Respir Crit Care Med, doi:10.1164/rccm.2009-040GL
Rajasurya, Gunasekaran, Damarla, Kolluru, A Fatal case of coronavirus disease 2019 (COVID-19) in a patient with idiopathic pulmonary fibrosis, Cureus n, doi:10.7759/cureus.8432
Tuite, Fisman, Odutayo, Bobos, Allen et al., COVID-19 hospitalizations, ICU admissions and deaths associated with the new variants of concern, Ontario COVID-19 Science Advisory Table, doi:10.47326/ocsat.2021.
Wong, Fidler, Marcoux, Johannson, Assayag et al., Practical considerations for the diagnosis and treatment of fibrotic interstitial lung disease during the coronavirus disease 2019 pandemic, Chest, doi:10.1016/j.chest.2020.04.019
Ye, Zhang, Wang, Huang, Song, Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review, Eur Radiol, doi:10.1007/s00330-020-06801-0
Yuan, Yin, Tao, Tan, Hu, Association of radiologic findings with mortality of patients infected with 2019 novel coronavirus in Wuhan, China, PLoS ONE, doi:10.1371/journal.pone.0230548
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop